Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment
Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.
You may also be interested in...
Three weeks after warning 10 firms, FDA publishes warnings identifying diabetes claims firms in New York and Tennessee; in August, it found so many violative claims by firms in Idaho and Oregon it might have been more efficient to identify diseases their products weren’t promoted to treat.
With the deadline looming for the UK to strike a Brexit agreement, industry groups Food Supplements Europe and CRN UK give their reactions to government plans to create a new Nutrition and Health Claims Committee to take on the role of EFSA in the event of a no deal.
In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.